Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of iptacopan in idiopathic immune complex membranoproliferative glomerulonephritis
MOH_2023-10-16_012991Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Primary immune complex membranoproliferative glomerulonephritis (MPGN) comparing Iptacopan arm with Placebo then open-label iptacopan arm (2 arms). Started Sep 2023; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
Primary immune complex membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on MOH_2023-10-16_012991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-16_012991.